Most organizations specialize in either frontier AI or frontier biology. CZI's Biohub integrates both to create a tight feedback loop. The AI models identify knowledge gaps, which in turn directs the biology team on what specific data sets to generate next. This flywheel of building bespoke data for model training accelerates discovery much faster than using pre-existing public data.

The next leap in biotech moves beyond applying AI to existing data. CZI pioneers a model where 'frontier biology' and 'frontier AI' are developed in tandem. Experiments are now designed specifically to generate novel data that will ground and improve future AI models, creating a virtuous feedback loop.

CZI’s mission to cure all diseases is seen as unambitious by AI experts but overly ambitious by biologists. This productive tension forces biologists to pinpoint concrete obstacles and AI experts to grasp data complexity, accelerating the overall pace of innovation.

Today's AI-first drug companies must bridge the gap between separate AI and biology experts. The future competitive advantage will belong to a new generation of scientists who are trained from the start to be fluent in both disciplines, eliminating the "accent" of learning one as a second language.

Instead of just augmenting existing wet lab workflows with AI, Sanofi's Norbert Furtman advocates for a paradigm shift. He suggests R&D leaders should design future workflows to be AI-driven from the start, with a customized wet lab built to serve as the 'perfect counterpart' to the in-silico tools.

In a significant strategic move, the Chan Zuckerberg Initiative acquired Evolutionary Scale, a top AI-for-biology team. Evolutionary Scale's CEO will now lead the entire Biohub program, a clear signal that AI leadership is fundamental to the future of its integrated biological research.

By selecting AI researcher Alex Reeves to head its science program, CZI is signaling a fundamental belief: AI is no longer just a tool for biology but is now the primary driver of discovery. Leadership must reflect this shift from a biology-first to an AI-led approach.

CZI operates at the intersection of two cultures: biologists who saw their goals as "crazy ambitious" and AI experts who saw them as "boring" and inevitable. Their strategy is to actively merge these fields to create breakthroughs that neither could achieve alone.

While acknowledging the power of Large Language Models (LLMs) for linear biological data like protein sequences, CZI's strategy recognizes that biological processes are highly multidimensional and non-linear. The organization is focused on developing new types of AI that can accurately model this complexity, moving beyond the one-dimensional, sequential nature of language-based models.